Explore

Trendline Trendline
Pfizer's TALZENNA and XTANDI Combination Shows Significant Improvement in Prostate Cancer Survival

Pfizer's TALZENNA and XTANDI Combination Shows Significant Improvement in Prostate Cancer Survival

Pfizer's TALZENNA and XTANDI Combination Shows Significant Improvement in Prostate Cancer Survival
Trendline Trendline
Pfizer's BRAFTOVI Regimen Shows Promising Results in Metastatic Colorectal Cancer Treatment

Pfizer's BRAFTOVI Regimen Shows Promising Results in Metastatic Colorectal Cancer Treatment

Pfizer's BRAFTOVI Regimen Shows Promising Results in Metastatic Colorectal Cancer Treatment
Trendline Trendline
Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment
Trendline Trendline
Pfizer's Phase 3 Trials Highlighted at ASCO 2026

Pfizer's Phase 3 Trials Highlighted at ASCO 2026

Pfizer's Phase 3 Trials Highlighted at ASCO 2026
Trendline Trendline
Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors

Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors

Exelixis Reports Positive Results from Phase 3 Trial of CABOMETYX in Neuroendocrine Tumors
Reuters Reuters
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage
Trendline Trendline
Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer

Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer

Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer
Trendline Trendline
Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026
Reuters Reuters
Experimental Novartis radiopharma drug shows promise in early study

Experimental Novartis radiopharma drug shows promise in early study

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent Biologics presented updated data from their Phase 1 proof-of-concept study of IBI363, a PD-1/IL-2α-bias bispecific fusion protein, at the 2026 American Society of Clinical Oncology Annual Meeting. The study focused on patients with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). IBI363 demonstrated robust survival benefits, with a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months in squamous NSCLC patients. The study also highlighted the potential for long-term survival benefits in patients with a smoking history. IBI363 is currently being evaluated in a global Phase 3 clinical study for IO-resistant squamous NSCLC.
Rapid Read Rapid Read
Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's investigational drug, atebimetinib, has shown promising results in a Phase 2a trial for pancreatic cancer, extending median overall survival by nearly nine months compared to standard treatments. The drug, combined with modified gemcitabine/nab-paclitaxel, demonstrated a median overall survival of 17.3 months. The trial results were presented at the American Society of Clinical Oncology (ASCO) meeting, highlighting the drug's potential as a first-line treatment for metastatic pancreatic cancer.
Trendline Trendline
Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO